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Abstract
Objective
Autoimmune hepatitis (AIH) is a chronic progressive liver disease. AIH is composed pre-
dominantly of type 1 in Japanese populations. The genetic and environmental factors are
associated with the pathogenesis of AIH. HLA-DRB1*03:01 and *04:01 are associated with
type 1 AIH in European and *04:05 in Japanese populations. Here, we conducted an HLA
association study in order to find HLA alleles or haplotypes predisposing or protective for
Japanese AIH.
Methods
HLA-DRB1 and DQB1 genotyping of 360 type 1 AIH patients and 1026 healthy controls was
performed.
Results
The predisposing association of DRB1*04:01 (P = 0.0006, corrected P [Pc] = 0.0193, odds
ratio [OR] 2.97, 95% confidence interval [CI] 1.62–5.43), DRB1*04:05 (P = 1.89×10−21,
Pc = 5.86×10−20, OR 3.41, 95% CI 2.65–4.38), and DQB1*04:01 (P = 4.66×10−18, Pc =
6.99×10−17, OR 3.89, 95% CI 2.84–5.33) and the protective association of DRB1*13:02 (P
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= 0.0003, Pc = 0.0080, OR 0.48, 95% CI 0.32–0.72) with Japanese type 1 AIH were
observed. An association of the DR4/DR8 heterozygous genotype with Japanese AIH was
identified for the first time (P = 3.12×10−9, OR 3.52, 95% CI 2.34–5.29). Susceptible diplo-
types were DRB1*04:05-DQB1*04:01/DRB1*08:02-DQB1*03:02 (P = 0.0004, OR 24.77,
95% CI 1.45–424.31) and DRB1*04:05-DQB1*04:01/DRB1*08:03-DQB1*06:01 (P =
1.18×10−6, OR 10.64, 95% CI 3.19–35.46). Serum levels of Immunoglobulin G and Immu-
noglobulin M, International Autoimmune Hepatitis Group score, positive rate of anti-smooth
muscle antibodies, and the rate of definite AIH were higher in AIH patients with DRB1*04:05
than without.
Conclusions
The important roles of specific combinations of DRB1 and DQB1 alleles or haplotypes in the
pathogenesis of type 1 AIH were suggested. The association of DR4/DR8 heterozygous
genotype suggested the pathologic importance of trans-complementing DQα-β heterodimer
molecules encoded by DQA1 allele of one haplotype and the DQB1 allele of the other haplo-
type, as it was proposed in the HLA association studies of Type 1 diabetes.
Introduction
Autoimmune hepatitis (AIH) is a very rare chronic progressive liver disease with autoimmune
features [1,2,3]. Type 1 AIH is characterized by the presence of serum anti-nuclear antibodies
(ANA) or anti-smooth muscle antibodies (ASMA) and type 2 AIH by type 1 liver-kidney
microsomal antibodies. AIH is composed predominantly of type 1 in Japanese populations.
Although the disease etiology is uncertain, it is considered that the genetic and environmental
factors are associated with the pathogenesis of AIH. Many studies including a recent genome-
wide association study [4] showed the genetic association of AIH with genes located within
human leukocyte antigen (HLA) region. HLA-DRB103:01 and 04:01 are associated with AIH
in European populations [5]; 04:05 is associated in Japanese and Korean populations [6,7,8,9].
In addition, several studies have shown that DRB104:04, 04:05, and 13:01 are associated
with AIH in Latin America [10,11,12,13]. DRB108 alleles are also reported to be associated
with AIH in Indian and Iranian, but not in Pakistani populations [14,15,16]. On the other
hands, DRB115:01 is protective for the susceptibility of AIH in European and Japanese popu-
lations [5,6]. DRB113:02, which differ by one amino acid residue from DRB113:01, is protec-
tively associated with AIH in Latin America [11,13,17] and in Japan [8].
It was reported in the genome-wide association study that HLA is the sole strong genetic
factor for the susceptibility of type 1 AIH [4]. The HLA region was scanned and the most
important loci for the susceptibility of type 1 AIH was reported to be DRB1 [18]. It was sug-
gested that no other genes in the HLA region are associated with type 1 AIH. However, DRB1
is in strong linkage disequilibrium with DQB1 and it is difficult to differentiate the role of
DRB1 and DQB1 in the pathogenesis of type 1 AIH. Although HLA alleles are known to confer
the risk for various autoimmune diseases, the precise mechanisms have not sufficiently been
revealed. The risk alleles are different in these autoimmune diseases [19]. It was considered
that different auto-antigens are presented by different disease-specific risk alleles; the pre-
sented auto-antigens are restricted by HLA alleles and are influenced by non-HLA genes, envi-
ronmental factors, or precipitating events. The complex of auto-antigens and risk alleles
HLA association with AIH
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stimulate self-reactive T cells, resulting in the eliciting of diseases [20]. In this study, we con-
ducted an HLA association study in order to search HLA alleles or haplotypes predisposing or
protective for Japanese AIH.
Materials and methods
Patients and healthy controls
Three hundred sixty type 1 AIH patients were enrolled from the register of Japanese National
Hospital Organization Liver Registry [21]. The AIH patients without any other types of liver
diseases satisfied the criteria of International Autoimmune Hepatitis Group (IAIHG) for diag-
nosis of type I AIH [22]. The healthy controls (n = 1026; mean age ± SD, 37.7 ± 11.7 years, 303
male [29.8%]) were recruited at Sagamihara Hospital, the University of Tokyo, Teikyo Univer-
sity, and Kanazawa University [23,24] or by the Pharma SNP Consortium (Tokyo, Japan) [25].
All the patients and the healthy individuals were native Japanese living in Japan. The study was
reviewed and approved by University of Tsukuba Research Ethics Committee, Nagasaki Uni-
versity Research Ethics Committee, and the NHO central Institutional Review Board.
Informed consents in writing were obtained from all the participants. The study was per-
formed in accordance with the principles expressed in the Declaration of Helsinki.
Genotyping methods
Genotyping of HLA-DRB1 and DQB1 was conducted by the polymerase chain reaction with
sequence-specific oligonucleotide probes (WAKFlow HLA typing kits, Wakunaga, Hiroshima,
Japan), using the Bio-Plex 200 system (Bio-Rad, Hercules, CA). HLA-DR4 serological group
includes DRB104:01, 04:03, 04:04, 04:05, 04:06, 04:07, and 04:10. DR6 is composed of
DRB113:01, 13:02, 14:03, 14:04, 14:05, 14:06, 14:07, 14:29, and 14:54. DR8 consists of
DRB108:02, 08:03, and 08:09. Genotyping results of HLA-DRB1 and DQB1 for some of the
AIH patients were previously reported [8]. Genotyping results of DRB1 for all of the healthy
controls (n = 1026) were previously reported [8,23,24]. Reported genotyping results of DQB1
for some of the healthy controls (n = 413; mean age ± SD, 39.3 ± 11.0 years, 61 male [14.8%])
were used for the analyses on DQB1 allele, DQB1 genotype, DRB1-DQB1 haplotype,
DRB1-DQB1 diplotype, and acid residues in the DQβ chain [24]. DRB1-DQB1 haplotypes were
elucidated by direct counting, because DRB1 is in strong linkage disequilibrium with DQB1.
Statistical analysis
Differences of AIH characteristics were analyzed by Mann-Whitney’s U test or Fisher’s exact
test using 2x2 contingency tables. Association of allele carrier frequencies, haplotype carrier
frequencies, or amino acid residue carrier frequencies was analyzed by Fisher’s exact test using
2x2 contingency tables under the dominant model. Differences of genotype frequencies or
diplotype (the specific combination of DRB1-DQB1 haplotypes) frequencies were analyzed by
Fisher’s exact test using 2x2 contingency tables. Adjustment for multiple comparisons was
conducted with Bonferroni method; corrected P (Pc) values were calculated by multiplying the
P value by the number of alleles or amino acid residues tested.
Results
Clinical features of type I AIH patients
Characteristics of the type I AIH patients are shown in Table 1. Among 360 AIH patients, 314
(87.2%) were positive for ANA, 118 (38.6%) were positive for ASMA. Of overall AIH, 227
(63.1%) were definite AIH.
HLA association with AIH
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HLA-DRB1 in type I AIH
To compare HLA-DRB1 allele carrier frequency of the AIH patients and the healthy controls, we
performed HLA-DRB1 genotyping (Table 2). A significant association between type I AIH and
DRB104:05 (P = 1.89×10−21, corrected P [Pc] = 5.86×10−20, odds ratio [OR] 3.41, 95% confi-
dence interval [CI] 2.65–4.38) was detected. DRB104:01was also associated with type I AIH
(P = 0.0006, Pc = 0.0193, OR 2.97, 95%CI 1.62–5.43). On the contrary, DRB113:02was found to
be protectively associated with type 1 AIH (P = 0.0003, Pc = 0.0080, OR 0.48, 95% CI 0.32–0.72).
HLA-DR4 serological group was associated with type I AIH (P = 3.84X10-18, OR 2.98, 95% CI
2.32–3.83), but DR6 is protectively associated (P = 2.10X10-5, OR 0.54, 95% CI 0.41–0.72). Thus,
DRB104:05 and DRB104:01were predisposing and DRB113:02was protective for AIH.
Demographic features of type I AIH patients with or without DRB104:05 or 13:02.
Clinical features of AIH patients with or without DRB104:05 or 13:02 were compared
(Table 3). Serum levels of Immunoglobulin G (IgG), Immunoglobulin M (IgM), and IAIHG
score were higher in AIH patients with DRB104:05 than without. Positive rate of ASMA and
the rate of definite AIH were higher in AIH patients with DRB104:05 than without. The com-
plication rate of cirrhosis tended to be higher in AIH patients with DRB113:02 than without.
Thus, specific clinical features of AIH patients possessing DRB104:05 were observed.
HLA-DRB1 genotype in type I AIH
We investigated the genotype frequency in the AIH patients (Table 4). The homozygosity for
DRB104:05 (OR 2.79, 95% CI 1.45–5.38) did not confer higher OR for AIH than heterozygosity
for DRB104:05 (OR 3.10, 95% CI 2.40–4.00). In contrast, the homozygosity for DRB113:02 (OR
0.15, 95% CI 0.01–2.56) conferred lower OR than heterozygosity for DRB113:02 (OR 0.51, 95%
Table 1. Characteristics of type I AIH patients.
AIH
Number 360
Male, n (%) 43 (11.9%)
Mean age, years (SD) 62.9 (±13.5)
Age at onset, years (SD) 59.1 (±13.5)
Albumin (g/dl) (SD) 3.8 (±0.6)
Total bilirubin (mg/dl) (SD) 3.7 (±4.9)
AST(IU/L) (SD) 469.7 (±546.2)
ALT(IU/L) (SD) 507.5 (±510.1)
ALP(IU/L) (SD) 465.2 (±211.0)
IgG (mg/dl) (SD) 2413.6 (±898.2)
IgM(mg/dl) (SD) 205.9 (±228.0)
Platelets (104/μl) (SD) 18.7 (±7.1)
ANA ≧ 1:40, n (%) 314 (87.2%)
ASMA≧ 1:40, n (%) 118 (38.6%)
Cirrhosis, n (%) 49 (13.6%)
IAIHG score (SD) 16.3 (±3.1)
Definite AIH, n (%) 227 (63.1%)
AIH: autoimmune hepatitis, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: Alkaline
Phosphatase, IgG: immunoglobulin G, IgG: immunoglobulin M, ANA: anti-nuclear antibody, ASMA: anti-
smooth muscle antibody, IAIHG: International Autoimmune Hepatitis Group. Numbers or average values of
each group are shown. Percentages or standard deviations are shown in parenthesis.
https://doi.org/10.1371/journal.pone.0187325.t001
HLA association with AIH
PLOS ONE | https://doi.org/10.1371/journal.pone.0187325 October 31, 2017 4 / 14
CI 0.34–0.78). The frequency of the DRB104:05/13:02 genotype was comparable. Of interest,
higher frequencies of DRB104:05/08:02 (P = 3.78X10-6, OR 6.70, 95% CI 2.89–15.54) and
DRB104:05/08:03 (P = 9.80X10-7, OR 4.54, 95% CI 2.47–8.35) genotypes in AIH were observed.
Similarly, the DR4/DR8 genotype frequency in AIH was markedly increased (P = 3.12×10−9, OR
3.52, 95% CI 2.34–5.29). Thus, some specific heterozygous genotypes were predisposing for AIH.
Certain amino acid residues in HLA-DRβ chains were associated with AIH
The association with AIH with respect to each amino acid residue in the HLA-DRβ chain was
analyzed. The amino acid residues of 11V, 13H, 33H, 57S, and 96Y in the DRβ chain showed
Table 2. HLA-DRB1 allele carrier frequency in the AIH patients and healthy controls.
Case
(n = 360)
Control (n = 1026) P OR Pc 95%CI
DRB1*01:01 26 (7.2) 110 (10.7) 0.0634 0.65 NS (0.42–1.01)
DRB1*03:01 1 (0.3) 3 (0.3) 1.0000 0.95 NS (0.10–9.16)
DRB1*04:01 22 (6.1) 22 (2.1) 0.0006 2.97 0.0193 (1.62–5.43)
DRB1*04:03 15 (4.2) 47 (4.6) 0.8823 0.91 NS (0.50–1.64)
DRB1*04:04 0 (0.0) 4 (0.4) 0.5780 0.32 NS (0.02–5.87)
DRB1*04:05 185 (51.4) 243 (23.7) 1.89X10-21 3.41 5.68X10-20 (2.65–4.38)
DRB1*04:06 15 (4.2) 76 (7.4) 0.0351 0.54 NS (0.31–0.96)
DRB1*04:07 5 (1.4) 15 (1.5) 1.0000 0.95 NS (0.34–2.63)
DRB1*04:10 12 (3.3) 32 (3.1) 0.8616 1.07 NS (0.55–2.10)
DRB1*07:01 2 (0.6) 9 (0.9) 0.7382 0.63 NS (0.14–2.94)
DRB1*08:02 35 (9.7) 72 (7.0) 0.1080 1.43 NS (0.93–2.18)
DRB1*08:03 58 (16.1) 153 (14.9) 0.6091 1.10 NS (0.79–1.52)
DRB1*08:09 0 (0.0) 2 (0.2) 1.0000 0.57 NS (0.03–11.87)
DRB1*09:01 77 (21.4) 280 (27.3) 0.0298 0.72 0.8949 (0.54–0.97)
DRB1*10:01 5 (1.4) 5 (0.5) 0.1381 2.88 NS (0.83–9.99)
DRB1*11:01 8 (2.2) 41 (4.0) 0.1361 0.55 NS (0.25–1.18)
DRB1*12:01 25 (6.9) 75 (7.3) 0.9059 0.95 NS (0.59–1.51)
DRB1*12:02 11 (3.1) 37 (3.6) 0.7384 0.84 NS (0.43–1.67)
DRB1*13:01 2 (0.6) 8 (0.8) 1.0000 0.71 NS (0.15–3.36)
DRB1*13:02 30 (8.3) 163 (15.9) 0.0003 0.48 0.0080 (0.32–0.72)
DRB1*14:02 1 (0.3) 0 (0.0) 0.2597 8.57 NS (0.35–210.76)
DRB1*14:03 5 (1.4) 44 (4.3) 0.0078 0.31 0.2337 (0.12–0.80)
DRB1*14:04 0 (0.0) 4 (0.4) 0.5780 0.32 NS (0.02–5.87)
DRB1*14:05 13 (3.6) 40 (3.9) 0.8744 0.92 NS (0.49–1.75)
DRB1*14:06 5 (1.4) 29 (2.8) 0.1655 0.48 NS (0.19–1.26)
DRB1*14:07 1 (0.3) 2 (0.2) 1.0000 1.43 NS (0.13–15.78)
DRB1*14:54 20 (5.6) 58 (5.7) 1.0000 0.98 NS (0.58–1.66)
DRB1*15:01 41 (11.4) 139 (13.5) 0.3171 0.82 NS (0.57–1.19)
DRB1*15:02 62 (17.2) 224 (21.8) 0.0692 0.74 NS (0.55–1.02)
DRB1*16:02 5 (1.4) 18 (1.8) 0.8119 0.79 NS (0.29–2.14)
DR4 238 (66.1) 406 (39.6) 3.84X10-18 2.98 (2.32–3.83)
DR6 (*13, *14) 74 (20.6) 332 (32.4) 2.10X10-5 0.54 (0.41–0.72)
DR8 92 (25.6) 220 (21.4) 0.1234 1.26 (0.95–1.66)
AIH: autoimmune hepatitis, OR: odds ratio, CI: confidence interval, Pc: corrected P value, NS: not significant. Allele carrier frequencies are shown in
parenthesis (%). Association was tested by Fisher’s exact test using 2x2 contingency tables under the dominant model.
https://doi.org/10.1371/journal.pone.0187325.t002
HLA association with AIH
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associations with AIH (Fig 1). Thus, this association analysis suggested roles for specific amino
acid residues in the HLA-DRβ chain.
HLA-DQB1 in type I AIH
We next tried to compare HLA-DQB1 allele carrier frequency of the AIH patients with 413 of
the 1026 healthy controls, since previously reported genotyping results of DQB1 were available
for the 413 healthy controls[24]. When DRB1 genotyping results for the 413 healthy controls
were compared with those of the AIH patients, similar tendencies were observed (S1 and S2
Tables). DQB104:01 allele was strongly associated with AIH (P = 4.66×10−18, Pc = 6.99×10−17,
OR 3.89, 95% CI 2.84–5.33, S3 Table). We further examined HLA-DQB1 genotype (S4 Table).
The homozygosity for DQB104:01 (OR 4.04, 95% CI 1.48–11.08) conferred comparative OR
compared with heterozygosity for DQB104:01 (OR 3.47, 95% CI 2.52–4.77). The higher fre-
quency of DQB104:01/06:01 genotype in AIH was observed (P = 8.75X10-6, OR 3.24, 95% CI
1.89–5.56). Thus, some of DQB1alleles or genotypes were predisposing for AIH.
DRB1-DQB1 haplotype in type I AIH
DRB1-DQB1 haplotype carrier frequencies were compared between the AIH patients and the
413 healthy controls (Table 5). Higher carrier frequencies of DRB104:01-DQB103:01
(P = 0.0007, OR 4.42 95% CI 1.77–11.01) and DRB104:05-DQB104:01 (P = 1.99×10−20, OR
4.32, 95% CI 3.14–5.96) were found in the AIH patients. DRB1-DQB1 diplotype frequencies
were also compared between the AIH patients and the 413 healthy controls (Table 5). The
homozygosity for DRB104:05-DQB104:01 (OR 5.07, 95% CI 1.69–15.20) conferred slightly
higher OR for AIH than heterozygosity for DRB104:05-DQB104:01 (OR 3.81, 95% CI 2.76–
5.28). The diplotype frequencies of DRB104:05-DQB104:01/DRB108:02-DQB103:02
Table 3. Comparison of the demographics between AIH patients with or without DRB1*04:05 or *13:02.
DRB1*04:05(+) DRB1*04:05(-) P DRB1*13:02(+) DRB1*13:02(-) P
Number 185 175 30 330
Male, n (%) 20 (10.8%) 23 (13.1%) *0.5193 2 (6.7%) 41 (12.4%) *0.5559
Age at onset, years (SD) 58.1 (±14.3) 59.2 (±14.7) 0.2897 59.5 (±15.8) 58.5 (±14.4) 0.6174
Mean age, years (SD) 63.2 (±12.2) 62.6 (±14.8) 0.6877 62.0 (±15.9) 63.0 (±13.3) 0.9408
Albumin (g/dl) (SD) 3.7 (±0.7) 3.8 (±0.9) 0.2699 3.7 (±0.6) 3.8 (±0.8) 0.2744
Total bilirubin (mg/dl) (SD) 3.6 (±4.6) 3.8 (±5.2) 0.8023 4.4 (±5.6) 3.6 (±4.9) 0.2202
AST(IU/L) (SD) 428.5 (±409.7) 513.2 (±659.0) 0.5735 498.4 (±498.4) 467.1 (±550.9) 0.7813
ALT(IU/L) (SD) 488.1 (±492.3) 525.1 (±529.0) 0.7793 549.4 (±562.2) 502.2 (±505.8) 0.8568
ALP(IU/L) (SD) 450.3 (±185.0) 478.4 (±237.1) 0.6656 463.8 (±217.1) 464.0 (±212.0) 0.9474
IgG (mg/dl) (SD) 2587.1 (±1005.7) 2119.8 (±840.8) 2.10X10-6 2242.9 (±878.5) 2370.6 (±964.3) 0.3771
IgM(mg/dl) (SD) 216.5 (±283.5) 144.1 (±126.2) 0.0020 140.3 (±125.5) 185.0 (±230.7) 0.1716
Platelets (104/μl) (SD) 18.5 (±7.1) 18.5 (±7.5) 0.9008 18.1 (±6.6) 18.5 (±7.4) 0.8625
ANA ≧ 1:40, n (%) 164 (88.6%) 150 (85.7%) *0.4328 29 (96.7%) 285 (86.4%) *0.1510
ASMA≧ 1:40, n (%) 91 (55.2%) 27 (19.1%) *6.46X10-11 7 (33.3%) 111 (38.9%) *0.6515
Cirrhosis, n (%) 26 (14.1%) 23 (13.1%) *0.8782 8 (26.7%) 41 (12.4%) *0.0462
IAIHG score (SD) 16.9 (3.1%) 15.6 (2.9%) 1.54X10-5 15.7 (2.9%) 16.3 (3.1%) 0.3476
Definite AIH, n (%) 133 (71.9%) 94 (53.7%) *0.0005 17 (56.7%) 210 (63.6%) *0.4383
Association was tested between AIH patients with or without DRB1*04:05 or *13:02 by Fisher’s exact test using 2x2 contingency tables or Mann-Whitney’s
U test.
*Fisher’s exact test was employed.
https://doi.org/10.1371/journal.pone.0187325.t003
HLA association with AIH
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(P = 0.0004, OR 24.77, 95% CI 1.45–424.31) and DRB104:05-DQB104:01/DRB108:03-
DQB106:01 (P = 1.18×10−6, OR 10.64, 95% CI 3.19–35.46) were higher in AIH patients,
suggesting the predisposing role of some specific heterozygous diplotypes in AIH.
Certain amino acid residues in HLA-DQβ chains were associated with
AIH
The association with AIH with respect to each amino acid residue in the HLA-DQβ chain was
analyzed in the comparison with the 413 healthy controls. The amino acid residues of 23L,
56L, 70E, and 71D in the DQβ chain showed associations with AIH (Fig 2). When each amino
acid residue frequency in the DRβ chain for the 413 healthy controls was compared with that
of the AIH patients, similar tendencies were observed (S1 Fig). Thus, this association analysis
suggested roles for specific amino acid residues in the HLA-DQβ chains.
Discussion
Several studies have reported that type 1 AIH is associated with HLA-DRB103:01 and DRB104:01
in European [5] and DRB104:05 in Japanese populations (Fig 3) [6,7,8]. In the present study, we
showed an association of Japanese AIH with DRB104:01 and 04:05, indicating the common pre-
disposing DRB104:01 allele for AIH between European and Japanese populations. DRB104:05 is
also common predisposing allele for AIH between Latin America [13] and Japan. In previous stud-
ies, DRB113:02was protectively associated with type 1 AIH in Latin America [11,13,17]. We also
confirmed a protective association of DRB113:02with Japanese AIH [8], but could not replicate
the protective effects of DRB115:01 [5,6]. These data indicated that the common protective
DRB113:02 allele for AIH between Latin America and Japan is also the protective allele shared by
multiple autoimmune diseases [19].
Specific demographic features of Japanese AIH patients with DRB104:05were observed
(Table 3). Elevated serum levels of IgG and IgM were detected in AIH patients with DRB104:05,
as it was previously described [7]. In the present study, the IAIHG score, the positive rate of
ASMA, and the rate of definite AIH were newly found to be higher in Japanese AIH patients
Table 4. HLA-DRB1 genotype frequency in the AIH patients and controls.
Case (n = 360) Control (n = 1026) P OR 95%CI
*04:05/not *04:05 167 (46.4) 224 (21.8) 5.72X10-18 3.10 (2.40–4.00)
*13:02/not *13:02 30 (8.3) 154 (15.0) 0.0011 0.51 (0.34–0.78)
*04:01/not *04:01 22 (6.1) 21 (2.0) 0.0003 3.11 (1.69–5.74)
*04:01/*04:05 4 (1.1) 1 (0.1) 0.0178 11.52 (1.28–103.39)
*04:05/*04:05 18 (5.0) 19 (1.9) 0.0035 2.79 (1.45–5.38)
*04:05/*08:02 18 (5.0) 8 (0.8) 3.78X10-6 6.70 (2.89–15.54)
*04:05/*08:03 27 (7.5) 18 (1.8) 9.80X10-7 4.54 (2.47–8.35)
*04:05/*13:02 8 (2.2) 25 (2.4) 1.0000 0.91 (0.41–2.04)
*13:02/*13:02 0 (0.0) 9 (0.9) 0.1225 0.15 (0.01–2.56)
DR4/DR4 34 (9.4) 57 (5.6) 0.0132 1.77 (1.14–2.76)
DR8/DR8 5 (1.4) 16 (1.6) 1.0000 0.89 (0.32–2.44)
DR6/DR6 3 (0.8) 25 (2.4) 0.0796 0.34 (0.10–1.12)
DR4/DR8 54 (15.0) 49 (4.8) 3.12X10-9 3.52 (2.34–5.29)
DR4/DR6 32 (8.9) 90 (8.8) 0.9144 1.01 (0.66–1.55)
AIH: autoimmune hepatitis, OR: odds ratio, 95%CI: confidence interval. Genotype frequencies are shown in parenthesis (%). Association was tested by
Fisher’s exact test using 2X2 contingency tables.
https://doi.org/10.1371/journal.pone.0187325.t004
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with DRB104:05. Although HLA alleles are known to confer the risk for various autoimmune
diseases, the precise mechanisms have not sufficiently been revealed. Thus, Japanese AIH
patients with DRB104:05 have typical clinical traits, probably because the auto-antigens
Fig 1. Associations of amino acid residues in DRβ chain with AIH. Each amino acid residue frequency in
the HLA-DRβ chain for the 1026 healthy controls was compared with that of the AIH patients. Differences of
amino acid residue carrier frequencies were analyzed by Fisher’s exact test using 2x2 contingency tables.
Corrected P (Pc) values were calculated by multiplying the P value by the number of amino acid residues
tested. Predisposing associations were indicated by filled circles and protective associations by open circles.
https://doi.org/10.1371/journal.pone.0187325.g001
Table 5. DRB1-DQB1 haplotype carrier or diplotype frequency in the AIH patients and controls.
DRB1-DQB1 haplotype Case
(n = 360)
Control
(n = 413)
P OR 95%CI
*04:01-*03:01 22 (6.1) 6 (1.5) 0.0007 4.42 (1.77–11.01)
*04:05-*04:01 182 (50.6) 79 (19.1) 1.99X10-20 4.32 (3.14–5.96)
*08:02-*03:02 21 (5.8) 21 (5.1) 0.7508 1.16 (0.62–2.15)
*08:02-*04:02 13 (3.6) 16 (3.9) 1.0000 0.93 (0.44–1.96)
*08:03-*03:01 3 (0.8) 2 (0.5) 0.6682 1.73 (0.29–10.39)
*08:03-*06:01 57 (15.8) 57 (13.8) 0.4768 1.17 (0.79–1.75)
*13:02-*06:04 31 (8.6) 49 (11.9) 0.1559 0.70 (0.44–1.12)
DRB1-DQB1 diplotype
*0405-*0401/not *04:05-*04:01 165 (45.8) 75 (18.2) 1.17X10-16 3.81 (2.76–5.28)
*04:05-*04:01/*04:01-*03:01 4 (1.1) 1 (0.2) 0.1898 4.63 (0.52–41.61)
*04:05-*04:01/*04:05-*04:01 17 (4.7) 4 (1.0) 0.0015 5.07 (1.69–15.20)
*04:05-*04:01/*08:02-*03:02 10 (2.8) 0 (0.0) 0.0004 24.77 (1.45–424.31)
*04:05-*04:01/*08:02-*04:02 7 (1.9) 3 (0.7) 0.2017 2.71 (0.70–10.56)
*04:05-*04:01/*08:03-*03:01 1 (0.3) 0 (0.0) 0.4657 3.45 (0.14–84.97)
*04:05-*04:01/*08:03-*06:01 26 (7.2) 3 (0.7) 1.18X10-6 10.64 (3.19–35.46)
*04:05-*04:01/*13:02-*06:04 8 (2.2) 8 (1.9) 0.8052 1.15 (0.43–3.10)
AIH: autoimmune hepatitis, OR: odds ratio, 95%CI: confidence interval. Genotype frequencies are shown in parenthesis (%). Association was tested by
Fisher’s exact test using 2X2 contingency tables.
https://doi.org/10.1371/journal.pone.0187325.t005
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presented by DRB104:05 molecules would be important for development of the typical clinical
traits of AIH.
It is well known that DRB104:01 in European [26,27] and DRB104:05 in Japanese popula-
tions [23,28] are associated with the susceptibility for rheumatoid arthritis (RA) and type 1 dia-
betes, in an analogous fashion to AIH. RA is a systemic autoimmune disease that affects
synovial joints. RA-susceptible DRB1 alleles shared a conserved amino acid sequence at posi-
tion 70–74 (QKRAA, RRRAA, or QRRAA) in HLA-DRβ chain and were designated as shared
epitope alleles [23,26]. The shared epitope alleles include DRB101:01, 04:01, 04:04, 04:05,
04:10, 10:01, 14:02, and 14:06. However, neither DRB101:01 nor 04:10 seems to be a risk
allele for AIH (Table 2). In the associations of DRB1 alleles with susceptibility to RA, a gene
dosage effect was reported; homozygosity for predisposing DRB1 alleles confers higher OR
than heterozygosity. However, we could not find any gene dosage effects of predisposing alleles
or haplotypes in AIH. These data suggested the differential roles of DRB1 in the pathogenesis
between AIH and RA.
Type 1 diabetes is an autoimmune disease that affects pancreatic β cells producing insulin,
resulting in the dysregulation of glucose metabolism. Susceptible DRB1 alleles for type 1
diabetes are DRB103:01, 04:01, 04:02, 04:04, 04:05, and 08:01 and protective alleles are
DRB115:01, 14:01, and 07:01 in European populations [27]. In Japanese populations,
DRB104:05, 08:02, and 09:01 are predisposing alleles for type 1 diabetes and DRB115:02 is a
protective allele [28]. No gene dosage effect was observed for DRB104:05, though a gene dos-
age effect for DRB109:01 was detected for type 1 diabetes. Similarly, we did not detect any
gene dosage effects of the predisposing DRB104:05 allele in AIH (Table 4). In addition, higher
frequencies of the DR3/DR4, DR4/DR4, and DR4/DR8 genotypes in type 1 diabetes were
reported [27]. In an analogous fashion, frequencies of the DR4/DR8 genotypes were higher
in Japanese type 1 AIH (Table 4). Since the allele frequency of DR4 is higher than that of
DR8 in Japanese populations, DR4 is a risk allele by itself, but DR8 is not, and type 1 AIH is a
Fig 2. Associations of amino acid residues in DQβ chain with AIH. Each amino acid residue frequency in
the HLA-DRβ chain for the 413 healthy controls was compared with that of the AIH patients. Differences of
amino acid residue carrier frequencies were analyzed by Fisher’s exact test using 2x2 contingency tables.
Corrected P (Pc) values were calculated by multiplying the P value by the number of amino acid residues
tested. Predisposing associations were indicated by filled circles and protective associations by open circles.
https://doi.org/10.1371/journal.pone.0187325.g002
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multifactorial disease, the DR4/DR8 genotype could not mainly contribute to the pathogenesis
of type 1 AIH. It was also reported that the association of DRB108 with the susceptibility of
type 1 AIH was not detected in European populations [29], because of low frequency of
DRB108. The DR4/DR8 heterozygous genotypes may cause an increased probability of self-
antigen presentation, resulting in the increased risk of the diseases. Thus, the manner of DRB1
association in type 1 AIH appears to be similar to that in type 1 diabetes.
Fig 3. Summary of the HLA-DRB1 alleles associated with type 1 AIH. The HLA-DRB1 alleles associated with type 1 AIH in
European, Japanese, and Hispanic populations are illustrated. The underlined alleles are protective alleles.
https://doi.org/10.1371/journal.pone.0187325.g003
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Augmented frequencies of the DR3/DR4 and DR4/DR8 heterozygous genotypes in type 1
diabetes was explained by the pathologic importance of trans-complementing DQα-β hetero-
dimer molecules encoded by the DQA1 allele of one haplotype and the DQB1 allele of the
other haplotype. The low stability of these molecules in trans was proposed to be causative to
type 1 diabetes [27,30]. Analogously, DR4/DR8 heterozygous genotype was increased in Japa-
nese type 1 AIH (Table 4), suggesting that trans-complementing DQα-β heterodimer mole-
cules might also play a role in AIH. DRB1-DQB1 diplotype analysis revealed that DRB104:05-
DQB104:01/DRB108:02-DQB103:02 and DRB104:05-DQB104:01/DRB108:03-DQB106:01
were significantly associated with AIH (Table 5). Japanese type 1 AIH was not significantly
associated with DRB108:02 or 08:03 (Table 2). Neither DQB103:02 nor 06:01was associated
with type 1 AIH (S1 Table). Based on the conserved haplotype structure in the Japanese popula-
tion, the DQA1 allele in the haplotype of DRB104:05-DQB104:01 is presumed to be DQA103:03
[31] and the DQA1 alleles in DRB108:02-DQB103:02 and DRB108:03-DQB106:01 are esti-
mated to be DQA103:01 and 01:03, respectively. The high risk diplotype DRB104:05-DQB104:
01/DRB108:02-DQB103:02 is considered to encode DQA103:03-DQB104:01 and DQA103:
01-DQB103:02 molecules in cis (DQα-β heterodimer molecules formed by the protein products
of DQA1 and the DQB1 alleles from the same chromosome) and DQA103:03-DQB103:02 and
DQA103:01-DQB104:01 molecules in trans (DQα-β heterodimer molecules formed by the pro-
tein products of DQA1 and the DQB1 alleles from the opposite chromosomes). The stabilities of
these four types of DQα-β heterodimer molecules were estimated to be low, according to the pre-
vious study [30]. The other high risk diplotype DRB104:05-DQB104:01/DRB108:03-DQB106:
01 is thought to encode DQA103:03-DQB104:01 and DQA101:03-DQB106:01 molecules in
cis and DQA103:03-DQB106:01 and DQA101:03-DQB104:01 molecules in trans. The stabili-
ties of these molecules except DQA101:03-DQB106:01 in cis were also estimated to be low [30].
In patients with the risk diplotype DRB104:05-DQB104:01/DRB108:03-DQB106:01, the low
stability of trans-complementing DQα-β heterodimer molecules could explain the pathogenesis
of type 1 AIH. In the case of type 1 diabetes, each of DRB1, DQA1, and DQB1 is believed to have
independent genetic contribution in the disease susceptibility based on the data from haplotype
analysis [27]. Similar scenario might also apply to AIH. However, such analysis could not be per-
formed in this study, because of the limited variety of DRB1-DQB1haplotypes in Japanese popula-
tions (Table 5). Furthermore, other culprit genes in linkage disequilibrium with DRB1-DQB1 loci
might be causative for AIH. Thus, the results of the association analyses of DRB1 and DQB1 in
type 1 AIH could propose several lines of explanations on the mechanisms underlined in the
pathogenesis.
We detected that amino acid residues of 11V, 13H, 33H, 57S, and 96Y in the HLA-DRβ
chain were associated with AIH (Fig 1A); these amino acids were encoded by DRB104:05
allele. It was also found that some amino acid residues of the DQβ chains were associated with
type 1 AIH (Fig 1B). These amino acid residues were also encoded by DQB104:01. These data
were influenced by the strongest predisposing haplotype DRB104:05-DQB104:01 for AIH,
confirming the dominance of the DRB104:05-DQB104:01 haplotype in type 1 AIH in Japa-
nese populations.
In conclusion, we showed the predisposing association of DRB104:01, DRB104:05, and
DQB104:01 and the protective association of DRB113:02 with Japanese type 1 AIH. The
association of DR4/DR8 heterozygous genotype with AIH was newly noted. With respect to
DRB1-DQB1 haplotypes, DRB104:01-DQB103:01 and DRB104:05-DQB104:01 haplotypes
were found to be associated with type 1 AIH. Of interest, the association of DRB104:05-
DQB104:01/DRB108:02-DQB103:02 and DRB104:05-DQB104:01/DRB108:03-DQB106:01
diplotypes was revealed. These data suggested the roles of specific combinations of DRB1
and DQB1 alleles or haplotypes in the pathogenesis of type 1 AIH. Further large scale studies
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should be performed to confirm these findings. In addition, because the HLA allele distribu-
tion pattern is different in other ethnic populations, it would be intriguing and informative to
analyze DRB1 and DQB1 alleles in type 1 AIH in other populations.
Supporting information
S1 Fig. Associations of amino acid residues in DRβ chain with AIH.
(PDF)
S1 Table. HLA-DRB1 allele carrier frequency in the AIH patients and the 413healthy con-
trols.
(PDF)
S2 Table. HLA-DRB1 genotype frequency in the AIH patients and the 413 healthy
controls.
(PDF)
S3 Table. HLA-DQB1 allele carrier frequency in the AIHpatients and the 413 healthy con-
trols.
(PDF)
S4 Table. HLA-DQB1 genotype frequency in the AIH patients andthe 413 healthy controls.
(PDF)
Acknowledgments
The members of the NHO-AIH study group are: Kiyoshi Migita (Fukushima Medical Uni-
versity School of Medicine), Minoru Nakamura (Nagasaki University Graduate School of
Biomedical Sciences), Hideo Nishimura (NHO Asahikawa Medical Center), Hironori Sakai
(NHO Beppu Medical Center), Eiichi Takezaki (NHO Higashi Hiroshima Medical Center),
Noboru Hirashima, Hironao Takahashi (NHO Higashi Nagoya National Hospital), Noriaki
Naeshiro (NHO Higashihiroshima Medical Center), Yukio Oohara (NHO Hokkaido Medi-
cal Center), Hajime Ohta (NHO Kanazawa Medical Center), Takeaki Sato (NHO Kokura
Medical Center), Kazuhiro Sugi (NHO Kumamoto Medical Center), Hiroshi Kouno (NHO
Kure Medical Center), Motoyuki Kohjima, Makoto Nakamuta (NHO Kyushu Medical Cen-
ter), Michio Kato, Iwao Yabuuchi (NHO Minami Wakayama Medical Center), Seigo Abiru,
Sung Kwan Bae, Shigemune Bekki, Satoru Hashimoto, Hiromi Ishibashi, Yuka Jiuchi, Atsu-
masa Komori, Shinya Nagaoka, Masashi Ohtani, Katsumi Yamasaki, Hiroshi Yatsuhashi
(NHO Nagasaki Medical Center), Masaaki Shimada (NHO Nagoya Medical Center), Fujio
Makita (NHO Nishigunma National Hospital), Toyokichi Muro (NHO Oita Medical Cen-
ter), Haruhiro Yamashita (NHO Okayama Medical Center), Eiji Mita (NHO Osaka Medical
Center), Taizo Hijioka (NHO Osaka Minami Medical Center), Eiji Mita (NHO Osaka
National Hospital), Yoko Nakamura, Yukio Watanabe (NHO Sagamihara National Hospi-
tal), Minoru Tomizawa (NHO Shimoshizu National Hospital), Kaname Yoshizawa (NHO
Shinshu Ueda Medical Center), Atsushi Naganuma (NHO Takasaki General Medical Cen-
ter), Masahiro Kikuchi (NHO Tokyo Medical Center), Hiroshi Kamitsukasa, Michiyasu
Yagura (NHO Tokyo National Hospital), Keisuke Ario (NHO Ureshino Medical Center),
Tatsuji Komatsu (NHO Yokohama Medical Center), Michio Yasunami (Saga-ken Medical
Centre Koseikan, Life Science Institute), and Hiroshi Furukawa (University of Tsukuba,
Faculty of Medicine).
HLA association with AIH
PLOS ONE | https://doi.org/10.1371/journal.pone.0187325 October 31, 2017 12 / 14
Author Contributions
Conceptualization: Hiroshi Furukawa, Michio Yasunami, Aya Kawasaki, Atsushi Takahashi,
Kazumichi Abe, Hiromasa Ohira, Naoyuki Tsuchiya, Kiyoshi Migita.
Data curation: Hiroshi Furukawa.
Formal analysis: Shomi Oka, Hiroshi Furukawa.
Funding acquisition: Michio Yasunami, Kiyoshi Migita.
Investigation: Shomi Oka, Hiroshi Furukawa, Michio Yasunami, Hitomi Nakamura.
Project administration: Kiyoshi Migita.
Resources: Minoru Nakamura, Atsumasa Komori, Seigo Abiru, Shinya Nagaoka, Satoru
Hashimoto, Atsushi Naganuma, Noriaki Naeshiro, Kaname Yoshizawa, Haruhiro Yama-
shita, Keisuke Ario, Hajime Ohta, Hironori Sakai, Iwao Yabuuchi, Hiroshi Yatsuhashi, Shi-
geto Tohma, Kiyoshi Migita.
Supervision: Michio Yasunami, Hiromasa Ohira, Naoyuki Tsuchiya, Kiyoshi Migita.
Writing – original draft: Shomi Oka.
Writing – review & editing: Hiroshi Furukawa, Aya Kawasaki, Hiromasa Ohira, Naoyuki
Tsuchiya, Kiyoshi Migita.
References
1. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006; 43(2
Suppl 1):S132–44. https://doi.org/10.1002/hep.21059 PMID: 16447290.
2. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006; 354(1):54–66. https://doi.org/10.1056/
NEJMra050408 PMID: 16394302.
3. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hep-
atitis. Gastroenterology. 2010; 139(1):58–72 e4. https://doi.org/10.1053/j.gastro.2010.04.053 PMID:
20451521.
4. de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al. Genome-wide
association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology.
2014; 147(2):443–52 e5. https://doi.org/10.1053/j.gastro.2014.04.022 PMID: 24768677.
5. Strettell MD, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, et al. Allelic basis for
HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997; 112(6):2028–35.
PMID: 9178696.
6. Umemura T, Katsuyama Y, Yoshizawa K, Kimura T, Joshita S, Komatsu M, et al. Human leukocyte anti-
gen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in
Japan. PLoS One. 2014; 9(6):e100565. https://doi.org/10.1371/journal.pone.0100565 PMID: 24956105.
7. Furumoto Y, Asano T, Sugita T, Abe H, Chuganji Y, Fujiki K, et al. Evaluation of the role of HLA-DR anti-
gens in Japanese type 1 autoimmune hepatitis. BMC Gastroenterol. 2015; 15(144):144. https://doi.org/
10.1186/s12876-015-0360-9 PMID: 26489422.
8. Maeda Y, Migita K, Higuchi O, Mukaino A, Furukawa H, Komori A, et al. Association between Anti-Gan-
glionic Nicotinic Acetylcholine Receptor (gAChR) Antibodies and HLA-DRB1 Alleles in the Japanese
Population. PLoS One. 2016; 11(1):e0146048. https://doi.org/10.1371/journal.pone.0146048 PMID:
26807576.
9. Lim YS, Oh HB, Choi SE, Kwon OJ, Heo YS, Lee HC, et al. Susceptibility to type 1 autoimmune hepati-
tis is associated with shared amino acid sequences at positions 70–74 of the HLA-DRB1 molecule. J
Hepatol. 2008; 48(1):133–9. https://doi.org/10.1016/j.jhep.2007.08.019 PMID: 18022727.
10. Vazquez-Garcia MN, Alaez C, Olivo A, Debaz H, Perez-Luque E, Burguete A, et al. MHC class II
sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol. 1998; 28
(6):985–90. PMID: 9672174.
11. Goldberg AC, Bittencourt PL, Mougin B, Cancado EL, Porta G, Carrilho F, et al. Analysis of HLA haplo-
types in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol. 2001; 62
(2):165–9. PMID: 11182227.
HLA association with AIH
PLOS ONE | https://doi.org/10.1371/journal.pone.0187325 October 31, 2017 13 / 14
12. Fortes Mdel P, Machado IV, Gil G, Fernandez-Mestre M, Dagher L, Leon RV, et al. Genetic contribution
of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Vene-
zuela. Liver Int. 2007; 27(10):1409–16. https://doi.org/10.1111/j.1478-3231.2007.01581.x PMID:
17927716.
13. Duarte-Rey C, Pardo AL, Rodriguez-Velosa Y, Mantilla RD, Anaya JM, Rojas-Villarraga A. HLA class II
association with autoimmune hepatitis in Latin America: a meta-analysis. Autoimmun Rev. 2009; 8
(4):325–31. https://doi.org/10.1016/j.autrev.2008.11.005 PMID: 19041429.
14. Kaur N, Minz RW, Anand S, Saikia B, Aggarwal R, Das A, et al. HLA DRB1 Alleles Discriminate the
Manifestation of Autoimmune Hepatitis as Type 1 or Type 2 in North Indian Population. J Clin Exp Hepa-
tol. 2014; 4(1):14–8. https://doi.org/10.1016/j.jceh.2013.12.002 PMID: 25755530.
15. Baharlou R, Faghihi-Kashani A, Faraji F, Najafi-Samei M, Setareh M, Zamani F, et al. HLA-DRB1
alleles of susceptibility and protection in Iranians with autoimmune hepatitis. Hum Immunol. 2016; 77
(4):330–5. https://doi.org/10.1016/j.humimm.2016.01.007 PMID: 26780502.
16. Hassan N, Siddiqui AR, Abbas Z, Hassan SM, Soomro GB, Mubarak M, et al. Clinical Profile and HLA
Typing of Autoimmune Hepatitis From Pakistan. Hepat Mon. 2013; 13(12):e13598. https://doi.org/10.
5812/hepatmon.13598 PMID: 24358040.
17. Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, et al. Pediatric and adult forms
of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology.
1999; 30(6):1374–80. https://doi.org/10.1002/hep.510300611 PMID: 10573514.
18. Yoshizawa K, Ota M, Katsuyama Y, Ichijo T, Matsumoto A, Tanaka E, et al. Genetic analysis of the HLA
region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol. 2005; 42(4):578–84. https://
doi.org/10.1016/j.jhep.2004.12.019 PMID: 15763345.
19. Furukawa H, Oka S, Tsuchiya N, Shimada K, Hashimoto A, Tohma S, et al. The role of common protec-
tive alleles HLA-DRB1*13 among systemic autoimmune diseases. Genes Immun. 2017; 2017(in
press). https://doi.org/10.1038/gene.2016.40 PMID: 27829665.
20. Koning F, Thomas R, Rossjohn J, Toes RE. Coeliac disease and rheumatoid arthritis: similar mecha-
nisms, different antigens. Nat Rev Rheumatol. 2015; 11(8):450–61. https://doi.org/10.1038/nrrheum.
2015.59 PMID: 25986717.
21. Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, Yagura M, et al. Hepatocellular carcinoma and
survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune
hepatitis prospective study). Liver Int. 2012; 32(5):837–44. https://doi.org/10.1111/j.1478-3231.2011.
02734.x PMID: 22221966.
22. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune
Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999; 31
(5):929–38. PMID: 10580593.
23. Oka S, Furukawa H, Kawasaki A, Shimada K, Sugii S, Hashimoto A, et al. Protective effect of the HLA-
DRB1*13:02 allele in Japanese rheumatoid arthritis patients. PLoS One. 2014; 9(6):e99453. https://doi.
org/10.1371/journal.pone.0099453 PMID: 24911054
24. Furukawa H, Oka S, Kawasaki A, Shimada K, Sugii S, Matsushita T, et al. Human Leukocyte Antigen
and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles,
DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. PLoS One. 2016; 11(4):e0154255.
https://doi.org/10.1371/journal.pone.0154255 PMID: 27116456.
25. Kamatani N, Kawamoto M, Kitamura Y, Harigai M, Okumoto T, Sumino Y. Establishment of B-cell lines
derived from 996 Japanese individuals. Tissue Culture Res Commun. 2004; 23(2):71–80.
26. Reveille JD. The genetic contribution to the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol.
1998; 10(3):187–200. PMID: 9608321
27. Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, et al. HLA DR-DQ haplotypes and
genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families. Diabe-
tes. 2008; 57(4):1084–92. https://doi.org/10.2337/db07-1331 PMID: 18252895.
28. Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Shintani M, Ono M, et al. Asian-specific HLA haplo-
types reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1
diabetes. Diabetes. 2002; 51(2):545–51. PMID: 11812768.
29. Miyadera H, Ohashi J, Lernmark A, Kitamura T, Tokunaga K. Cell-surface MHC density profiling reveals
instability of autoimmunity-associated HLA. J Clin Invest. 2015; 125(1):275–91. https://doi.org/10.1172/
JCI74961 PMID: 25485681.
30. Nakajima F, Nakamura J, Yokota T. Analysis of HLA haplotypes in Japanese, using high resolution
allele typing. MHC. 2001; 8(1):1–32.
HLA association with AIH
PLOS ONE | https://doi.org/10.1371/journal.pone.0187325 October 31, 2017 14 / 14
